Piper Jaffray analyst Matt O'Brien downgraded Endologix to Neutral and lowered his price target for the shares to $4.75 from $7. The big news from the company's Q2 results is that management is meaningfully reducing revenue guidance for the year as it moves to revamp the business, O'Brien tells investors in a research note. Changes are a good idea "but the risks here are steep (lingering employee disruption, product safety concerns) compared to the rewards ," the analyst contends. He wants to move to the sidelines and see how the reorganization of the business takes shape.